Treatment of Progressive Radioiodine-Refractory Papillary Thyroid Cancer with BRAF V600E Mutation
Clinical Scenario
This protocol addresses patients with progressive radioiodine-refractory (RAIR) papillary thyroid carcinoma whose tumour harbours an oncogenic BRAF V600E mutation — a molecularly defined subgroup requiring a targeted therapeutic approach.
Specific Situation
In this setting, BRAF V600E-directed therapy may be considered as a first-line option, particularly for patients who are poor candidates for standard multikinase inhibitor therapy. Confirming BRAF V600E mutation status is central to identifying eligible patients.
Treatment Approach (Overview)
The regimen involves BRAF-directed therapy — the specific agent selection and combination strategy are defined within the full protocol.
Full regimen, sequencing, and agent details available via the link below →
References
- In patients with progressive RAIR DTC harboring an oncogenic BRAF V600E mutation, BRAF V600E-directed therapy may be considered in the first line for patients who are poor candidates for lenvatinib.
- BRAF-directed treatment is recommended in patients with BRAF V600E mutation-positive RAIR DTC who have progressed on or did not tolerate one or more prior MKI therapies.
- Dabrafenib plus trametinib was not superior to dabrafenib alone in progressive DTC; thus, dabrafenib monotherapy may be considered.
DOI: 10.1177/10507256251363120
View source ↗